Virginia Governor Vetoes Bill for Lower Prescription Drug Costs
Drug Topics
APRIL 10, 2024
Governor Glenn Youngkin vetoed bills HB570 and SB274 that would have allowed the state to establish its first Prescription Drug Affordability Board.
Wed.Apr 10, 2024
568 
What’s old is new: The revival of a one-time radiotherapy cancer treatment
PharmaVoice
APRIL 10, 2024
TAE Life Sciences is bringing radiation-based cancer therapy to clinical trials globally in the coming years.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Buyer Beware: Red Yeast Rice Supplements Linked to Deaths, Hospitalizations
Drug Topics
APRIL 10, 2024
Japan’s health ministry has issued a warning to consumers regarding red yeast rice dietary supplements containing a red species of mold after 5 people died and more were hospitalized after consumption.
Psychiatry drugs finally have pharma’s attention. Can they keep it?
PharmaVoice
APRIL 10, 2024
Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
How Pharmacies Can Successfully Leverage 340B
Drug Topics
APRIL 10, 2024
Eric Fromhart, co-founder and chief growth officer at Aventi Health, discusses how pharmacies can use 340B to increase profits and how they can avoid any potential risks when participating in the program.
STAT+: Cancer vaccines gain momentum, after years of disappointing results
STAT
APRIL 10, 2024
SAN DIEGO — Cancer vaccines have traveled a potholed road over the last decade. But as researchers from different companies and academic institutions presented promising early data at the American Association for Cancer Research annual meeting in San Diego this week, experts said there’s a collective feeling of turning a corner. “There’s a lot more interest in vaccines” now that the technology is improving, said Roy Herbst, chief of medical oncology at Yale Can
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
STAT+: Vertex to buy Alpine Immune Sciences for $4.9 billion
STAT
APRIL 10, 2024
Vertex Pharmaceuticals will buy Alpine Immune Sciences, a maker of protein-based medicines that harness the immune system, for $4.9 billion, the companies announced Wednesday. It is the largest acquisition in Vertex’s history. The acquisition gives Vertex a drug called povetacicept, which has shown promise in treating IgA nephropathy (IgAN), an autoimmune disorder of the kidney that can lead to end-stage renal disease and affects 130,000 people in the U.S.
Who Is Taking Care of Pharmacists?
Drug Topics
APRIL 10, 2024
“Every pharmacist raises their hand and takes an oath before they graduate to put patients first,” said Bruce Berger, PhD, FAPhA. “But what happens when you exist in an environment every single day where that’s impossible?
STAT+: Did you say 486%? Why one company thinks such a price hike for its drug is justified
STAT
APRIL 10, 2024
In an era when huge price hikes for prescription drugs are almost guaranteed to draw criticism, is there any circumstance when a 486% increase for a medicine might appear to be justified? A small company called Harrow argues that it can make the case for an injectable eye treatment that has been used to combat several serious conditions. Company executives maintain the medication, which has been largely out of stock for the past few years, requires substantial investment in order to restore a st
Psychedelic Medicine Could Fill Care Gap in Psychiatric Care
Pharmacy Times
APRIL 10, 2024
However, psychedelic medicine has a variety of barriers, including historical perception, access challenges, legal obstacles, and ethical questions.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
NCI director expresses optimism about next era of cancer research, despite shrinking budget and brain drain
STAT
APRIL 10, 2024
SAN DIEGO — Kimryn Rathmell, director of the National Cancer Institute, gestured toward the screen and asked an audience of clinicians, researchers, and patient advocates what they thought they were looking at. Projected behind her was a patchwork of purple, red, pink, and blue squares. Moments later, a larger-than-life image of Taylor Swift flashed in the middle of the pattern, and laughter rippled through the room here at the American Association for Cancer Research annual meeting as at
FDA Approves Cilta-Cel for Treatment of Relapsed, Refractory Multiple Myeloma
Pharmacy Times
APRIL 10, 2024
The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.
STAT+: Drug shortages reached a record high as 2023 drew to a close
STAT
APRIL 10, 2024
The number of ongoing and active drug shortages in the U.S. stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country. Unresolved shortages have, in fact, been hovering above 300 for more than a year as numerous basic and life-saving medicines are in short supply.
AMA: 80% of docs have lost revenue amid disruptions from Change Healthcare cyberattack
Fierce Healthcare
APRIL 10, 2024
Most physicians felt the disruption caused by the cyberattack on Change Healthcare, and many were still seeing the effects in early April, more than a month after the hacking was revealed, accordin | Most physicians felt the disruption caused by the cyberattack on Change Healthcare, and many were still seeing the effects in early April, more than a month after the hacking was revealed, according to a new survey from the American Medical Association.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT+: BIO’s top lobbyist exits, signaling reorganization
STAT
APRIL 10, 2024
WASHINGTON — The biotech industry’s largest trade group has parted ways with its top lobbyist, the group confirmed to STAT, adding to a recent bout of organizational tumult. The departure of Nick Shipley may be part of a greater shake-up spearheaded by the Biotechnology Innovation Organization’s new CEO, John Crowley, who took over in December.
UK calls time-out on post-Brexit rules opposed by industry
pharmaphorum
APRIL 10, 2024
The UK has agreed to delay border checks on products used in life sciences R&D and manufacturing, says industry group BIA.
Opinion: Cancer is a killer. So is the fear of it
STAT
APRIL 10, 2024
The widespread attention to the recent revelations of cancer diagnoses by Princess Catherine , actress Olivia Munn , and King Charles , among others, demonstrate yet again that cancer is a feared disease. For good reason: It is a cruel killer, the second leading cause of death in the U.S. and a top killer around the world. So public faith in cancer screening (checking seeming healthy people for signs of hidden disease) is deep, driven by the widespread understanding that finding cancer early &#x
Sunshine transparency reporting for emerging pharma: Simplify, streamline, and secure
pharmaphorum
APRIL 10, 2024
Discover how Sunshine transparency reporting can be simplified, streamlined, and secured for emerging pharmaceutical companies with a focus on Healthcare Professionals (HCP) and Healthcare Organisations (HCO).
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT+: Regeneron accused by Justice Department of manipulating Medicare pricing
STAT
APRIL 10, 2024
The U.S. Department of Justice filed a lawsuit accusing Regeneron Pharmaceuticals of manipulating Medicare pricing by inflating the average sales price for its expensive and widely prescribed Eylea treatment for serious eye disease. In its lawsuit, the Justice Department claimed the company failed for more than a decade to report how it paid “hundreds of millions of dollars” to subsidize Eylea purchases by reimbursing drug distributors for credit-card processing fees.
State public option plans don't reduce premiums, result in low enrollment: industry-backed study
Fierce Healthcare
APRIL 10, 2024
Instead of enacting public option plans, states should target reinsurance programs, a new report from the Partnership for America's Health Care Future argues. | Public option plans may not be reducing premiums and expanding coverage as previously thought they would, a new study shows.
Essential adds neuroblastoma drug with Renaissance buy
pharmaphorum
APRIL 10, 2024
Essential Pharma has bought Renaissance Pharma, adding its first developmental drug candidate, a therapy for rare cancer neuroblastoma.
Opinion: Mental health screening tools for kids are 30 years out of date
STAT
APRIL 10, 2024
Suicide is the second leading cause of death among children aged 10 to 14 in the U.S. That’s evidence of a systemic failure in identifying and addressing mental health concerns in young people. Compounding the problem is the average delay of 11 years between the onset of a mental health condition and its diagnosis. Think about it: a child exhibiting signs of mental health challenges at age 6 may not receive proper diagnosis or treatment until age 17.
Can pink eye cause a fever?
The Checkup by Singlecare
APRIL 10, 2024
You’re shivering one minute and sweating the next. A fever can be a sign you caught the latest flu that’s circulating in the community. However, this unpleasant symptom can accompany many different conditions, including conjunctivitis , the medical term for pink eye. “Conjunctivitis could stem from a viral infection, and when this occurs, someone may also have other symptoms such as fever, body aches, nasal discharge, and cough ,” says Edgar Navarro Garza , MD, a board-certified pediatrician at
Biosimilars in Retina Space Expected to Grow in 2024, Coming Years
Pharmacy Times
APRIL 10, 2024
In a review, investigators focused on ranibizumab (Lucentis; Genentech), aflibercept (Eylea; Regeneron), and bevacizumab (Avastin; Genentech) as growth opportunities in the biosimilar space.
Changing Faces: Digital and supplier hires from March 2024
pharmaphorum
APRIL 10, 2024
Discover the latest trends in leadership appointments and C-suite hires in the digital and supplier space from March 2024 in our in-depth analysis.
Study Suggests Patients With Low-Risk CLL May Stop Specialized Follow-Up Visits
Pharmacy Times
APRIL 10, 2024
The results demonstrated similar overall survival between patients with chronic lymphocytic leukemia who discontinued specialized follow-ups versus those who continued.
How Efficient Logistics Can Change the Lives of Rare Disease Patients
Pharmaceutical Commerce
APRIL 10, 2024
If manufacturers cannot ensure safe, cost-effective delivery of treatments for rare diseases, access will remain a challenges for many patients living with these conditions.
e-therapeutics is latest UK biotech to seek AIM de-listing
pharmaphorum
APRIL 10, 2024
e-therapeutics is the latest UK biotech to say it plans to delist from the AIM, citing a lack of interest from institutional investors.
STAT+: Pharmalittle: We’re reading about a 486% drug price hike, AstraZeneca CEO pay, and more
STAT
APRIL 10, 2024
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.
Vertex wagers $4.9bn on Alpine kidney disease therapy
pharmaphorum
APRIL 10, 2024
In another departure from its focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA nephropathy (IgAN). The $65-per-share deal is due to close within the next three months, said Vertex, which plans to fund the acquisition with cash in hand. It is the largest acquisition in the biopharma sector so far in 2024.
Pharma Pulse 4/10/24: 7% of Patients with Cancer Participate in Research, Technologies Being Used to Enhance Trial Enrollment and Diversity & more
Pharmaceutical Commerce
APRIL 10, 2024
The latest news for pharma industry insiders.
Roche gets EU okay for first HER2-low test kit
pharmaphorum
APRIL 10, 2024
Roche gets EU approval for its HER2-low companion diagnostic, used to identify breast cancer patients eligible for treatment with Enhertu.
Women in Science: Elisa Cascade on why women should never be afraid to ask
Outsourcing Pharma
APRIL 10, 2024
Elisa Cascade is the chief product officer at Advarra and is responsible for driving the clinical research company's technology product vision and management. We had a fascinating and inspiring conversation with her - touching on imposter syndrome, how to avoid suffering in silence and her 'just do it' mantra.
Let's personalize your content